| Content type |
|
| Collection(s) |
|
| Title |
|
| Resource Type |
|
| Description |
Description
One of the newest advancements in the treatment and control of giaucoma is timolol maleate. Timolol maleate is described as a nonselective blocking agent of B1, and B2 adrenergic receptors. When applied topically to the eye it has the action of reducing
elevated as well as normal intraocular pressure . Unlike some B-adrenergic blocking agents, timolol does not have sympathomimetic effects nor local anesthetic (membrane-stabilizing) activity. Timolol maleate is currently produced and marketed in ophthalmic
solution by Merck Sharp & Dohme under the trade name Timoptic*. The purpose of this paper is to discuss the clinical nature, actions, indications and usasage, ontraindications and precautions, adverse
reactions, and dosage and administrationo
|
| Handle |
Handle
http://hdl.handle.net/2323/4674
|
| Persons |
|
| Genre |
|
| Subject |
|
| Origin Information |
|
| Note |
Note
This paper is submitted in partial fulfillment of the requirements for the degree of Doctor of Optometry. 8 pages.
|
| Related Item |
|
| Language |
|
